Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: We will address the following questions: 1) Do NSAIDs prevent the onset of Parkinson's disease(PD)? We will seek primary prevention trials and epidemiological studies examining the association between NSAIDs and PD to address this question. 2) Are NSAIDs neuroprotective in PD ‐ do they slow the progression of disease once PD is established? We will seek secondary prevention trials to address this question. We will also explore any adverse effects of taking NSAIDs. 3) What are the adverse effects of taking NSAIDs in PD? We will use studies in question 2 above to examine this, along with any additional studies identified from the searching (including case studies and case series).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Glial reactions in Parkinson's disease
McGeer, P. L., & McGeer, E. G. (2008) · Movement Disorders · doi:10.1002/mds.21751 · Cited by 701
Etminan, M., Gill, S., & Samii, A. (2003) · BMJ · doi:10.1136/bmj.327.7407.128 · Cited by 511
A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment
on behalf of the Rofecoxib Protocol 078 study group, Thal, L. J., Ferris, S. H., Kirby, L., Block, G. A., Lines, C. R., Yuen, E., Assaid, C., Nessly, M. L., Norman, B. A., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300690 · Cited by 402
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial
ADAPT Research Group (2007) · Neurology · doi:10.1212/01.wnl.0000260269.93245.d2 · Cited by 354
Szekely, C. A., Green, R. C., Breitner, J. C. S., Østbye, T., Beiser, A. S., Corrada, M. M., Dodge, H. H., Ganguli, M., Kawas, C. H., Kuller, L. H., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000313933.17796.f6 · Cited by 121
Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J., et al. (2003) · JAMA · doi:10.1001/jama.289.21.2819 · Cited by 5
Research works printed but not linked: 18
- 2008, Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial, Lancet Neurology, 7, 41, 10.1016/S1474-4422(07)70293-4 · DOI
- Aisen, 2002, Randomized pilot study of nimesulide treatment in Alzheimer's disease, Neurology, 58, 1050, 10.1212/WNL.58.7.1050 · DOI · Paper page
- Asanuma, 2007, Common anti-inflammatory drugs are potentially therapeutic for Parkinson's disease?, Experimental Neurology, 206, 172, 10.1016/j.expneurol.2007.05.006 · DOI
- Asanuma, 2008, Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and Parkinson's disease, Current Pharmaceutical Design, 14, 1428, 10.2174/138161208784480153 · DOI
- Breitner, 2009, Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort, Neurology, 72, 1899, 10.1212/WNL.0b013e3181a18691 · DOI · Paper page
- Reeves, 2008, Chapter 13: Including non-randomised studies, 10.1002/9780470712184.ch13 · DOI · Paper page
- de-Craen, 2005, Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia, American Journal of Epidemiology, 161, 114, 10.1093/aje/kwi029 · DOI · Paper page
- Esposito, 2007, Non-steroidal anti-inflammatory drugs in Parkinson's disease, Exp.Neurol., 205, 295, 10.1016/j.expneurol.2007.02.008 · DOI · Paper page
- Hernan, 2006, Non-steroidal antiinflammatory drugs and the incidence of Parkinson's disease, Neurology, 66, 1097, 10.1212/01.wnl.0000204446.82823.28 · DOI · Paper page
- Klegeris, 2007, Therapeutic approaches to inflammation in neurodegenerative disease, Current Opinion in Neurology, 20, 351, 10.1097/WCO.0b013e3280adc943 · DOI · Paper page
- Reines, 2004, Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study, Neurology, 62, 66, 10.1212/WNL.62.1.66 · DOI · Paper page
- Scharf, 1999, A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease, Neurology, 53, 197, 10.1212/WNL.53.1.197 · DOI · Paper page
- Smith, 2008, Inflammation in Parkinson's disease: an update, Current Opinion in Investigational Drugs, 9, 478
- Szekely, 2004, Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review, Neuroepidemiology, 23, 159, 10.1159/000078501 · DOI · Paper page
- Tabet, 2002, Indomethacin for Alzheimer's disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD003673 · DOI · Paper page
- Tabet, 2003, Ibuprofen for Alzheimer's disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD004031 · DOI
- Wersinger, 2006, An inflammatory pathomechanism for Parkinson's disease?, Current Medicinal Chemistry, 13, 591, 10.2174/092986706776055760 · DOI · Paper page
- Whitton, 2007, Inflammation as a causative factor in the aetiology of Parkinson's disease, British Journal of Pharmacology, 150, 963, 10.1038/sj.bjp.0707167 · DOI · Paper page
Cited by
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310
Meta‐analysis of early nonmotor features and risk factors for Parkinson disease
Noyce, A. J., Bestwick, J. P., Silveira‐Moriyama, L., Hawkes, C. H., Giovannoni, G., Lees, A. J., & Schrag, A. (2012) · Annals of Neurology · doi:10.1002/ana.23687 · Cited by 778
Neuroinflammation: The role and consequences
Lyman, M., Lloyd, D. G., Ji, X., Vizcaychipi, M. P., & Ma, D. (2014) · Neuroscience Research · doi:10.1016/j.neures.2013.10.004 · Cited by 730
Han, X., Sun, S., Sun, Y., Song, Q., Zhu, J., Song, N., Chen, M., Sun, T., Xia, M., Ding, J., et al. (2019) · Autophagy · doi:10.1080/15548627.2019.1596481 · Cited by 408
Athauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
Epidemiology of Parkinson Disease
Lee, A., & Gilbert, R. M. (2016) · Neurologic Clinics · doi:10.1016/j.ncl.2016.06.012 · Cited by 366
Neurodegeneration and Inflammation—An Interesting Interplay in Parkinson’s Disease
Marogianni, C., Sokratous, M., Dardiotis, E., Hadjigeorgiou, G. M., Bogdanos, D., & Xiromerisiou, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228421 · Cited by 366
Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson’s Disease
Subramaniam, S. R., & Federoff, H. J. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00176 · Cited by 347
Insulin resistance and Parkinson’s disease: A new target for disease modification?
Athauda, D., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 328
Effects of Nonsteroidal Anti-Inflammatory Drugs at the Molecular Level
Gunaydin, C., & Bilge, S. S. (2019) · The Eurasian Journal of Medicine · doi:10.5152/eurasianjmed.2018.0010 · Cited by 284
The ongoing pursuit of neuroprotective therapies in Parkinson disease
Athauda, D., & Foltynie, T. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.226 · Cited by 269
Immune aging, dysmetabolism, and inflammation in neurological diseases
Deleidi, M., Jäggle, M., & Rubino, G. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00172 · Cited by 260
The Ageing Brain: Molecular and Cellular Basis of Neurodegeneration
Azam, S., Haque, M. E., Balakrishnan, R., Kim, I.-S., & Choi, D.-K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.683459 · Cited by 255
Lindqvist, D., Kaufman, E., Brundin, L., Hall, S., Surova, Y., & Hansson, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047387 · Cited by 236
Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson’s Disease
Li, Y., Xia, Y., Yin, S., Wan, F., Hu, J., Kou, L., Sun, Y., Wu, J., Zhou, Q., Huang, J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.719807 · Cited by 230
Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches
Hussain, R., Zubair, H., Pursell, S., & Shahab, M. (2018) · Brain Sciences · doi:10.3390/brainsci8090177 · Cited by 229
Inflammation in Parkinson’s disease: role of glucocorticoids
Herrero, M.-T., Estrada, C., Maatouk, L., & Vyas, S. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00032 · Cited by 175
Karpenko, M. N., Vasilishina, A. A., Gromova, E. A., Muruzheva, Z. M., & Bernadotte, A. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.02.011 · Cited by 172
Neuroinflammation in Parkinson's disease: role in neurodegeneration and tissue repair
Vivekanantham, S., Shah, S., Dewji, R., Dewji, A., Khatri, C., & Ologunde, R. (2015) · International Journal of Neuroscience · doi:10.3109/00207454.2014.982795 · Cited by 171
Sarkar, S., Rokad, D., Malovic, E., Luo, J., Harischandra, D. S., Jin, H., Anantharam, V., Huang, X., Lewis, M., Kanthasamy, A., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aat9900 · Cited by 171
Peng, B., Yang, Q., B Joshi, R., Liu, Y., Akbar, M., Song, B.-J., Zhou, S., & Wang, X. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072316 · Cited by 156
The DNA Damage Response in Neurons: Die by Apoptosis or Survive in a Senescence-Like State?
Fielder, E., von Zglinicki, T., & Jurk, D. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161221 · Cited by 126
Tentillier, N., Etzerodt, A., Olesen, M. N., Rizalar, F. S., Jacobsen, J., Bender, D., Moestrup, S. K., & Romero-Ramos, M. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1636-16.2016 · Cited by 109
Microglia-targeting nanotherapeutics for neurodegenerative diseases
Zhao, N., Francis, N. L., Calvelli, H. R., & Moghe, P. V. (2020) · APL Bioengineering · doi:10.1063/5.0013178 · Cited by 104
Bassani, T. B., Vital, M. A. B. F., & Rauh, L. K. (2015) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20150057 · Cited by 78
Anti‐inflammatory treatment rescues memory deficits during aging in nfkb1−/− mice
Fielder, E., Tweedy, C., Wilson, C., Oakley, F., LeBeau, F. E. N., Passos, J. F., Mann, D. A., von Zglinicki, T., & Jurk, D. (2020) · Aging Cell · doi:10.1111/acel.13188 · Cited by 71
Immunomodulators as Therapeutic Agents in Mitigating the Progression of Parkinson’s Disease
Grimmig, B., Morganti, J., Nash, K., & Bickford, P. (2016) · Brain Sciences · doi:10.3390/brainsci6040041 · Cited by 17
Metadata
- Authors
- Rees, K., Stowe, R., Patel, S., Ives, N., Breen, K., Clarke, C. E., & Ben-Shlomo, Y.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2010-04-14
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W4234799259
- Cited by
- 120
- References
- 8
- Type
- reference entry
- Language
- en
- Update notices
- new_version (2011-11-09)
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.